AbbVie, the North Chicago-based pharmaceutical heavyweight behind Humira and Botox, sued the federal government on Wednesday, asking a judge to tighten the definition of who qualifies as a “patient” under the 340B drug-discount program. The move puts one of the region’s largest employers at the center of a national fight over how safety-net hospitals and clinics secure discounts on outpatient medications.
What AbbVie wants from the court
In its complaint, AbbVie asks the court to scrap long-standing agency guidance and replace it with a narrower reading of the 340B statute. The company is pushing for a more restrictive test that would confine 340B discounts to prescriptions connected to recent, substantive care coordinated by the covered entity itself.
AbbVie’s news release describes a four-part test, including a requirement that the provider directly manage the patient’s condition and have seen the patient within the previous 12 months. The company argues that the current standards open the door to “program abuses.” As reported by Reuters, AbbVie filed the case in the U.S. District Court for the District of Columbia. For AbbVie’s full statement, see AbbVie.
Why hospitals say the program matters
Hospital groups and 340B advocates counter that the discounts are a financial lifeline that helps fund community health programs, free medication services, and other support for patients with low incomes. According to HRSA, covered-entity purchases under 340B reached $66.3 billion in 2023, a figure that hints at just how much money is on the line.
Organizations representing hospitals have pushed back against manufacturer limits and warned that further restrictions could force cuts to services for vulnerable patients. For their perspective on recent federal oversight and manufacturer actions, see 340B Health.
Legal stakes for the program
AbbVie’s lawsuit also claims that HRSA turned down its requests to audit certain covered entities, which the company describes as blocking a key safeguard that manufacturers can use to police compliance. Bloomberg Law reported that AbbVie accused the agency of “unlawfully denied” audit requests, and legal observers note that the case joins a growing list of courtroom battles over 340B.
Recent appellate decisions have allowed some False Claims Act cases tied to 340B pricing practices to proceed, adding another layer of risk for participants on all sides. For a deeper dive into that litigation trend, see Husch Blackwell.
What to watch next
The case is now in federal court in Washington, D.C., where the government’s response and any efforts by hospital groups to intervene will determine how quickly the judge gets to the core legal questions. Expect dueling briefs from drugmakers, HRSA and hospital associations in the coming weeks as the future of the 340B framework continues to play out in court and in Congress.
As noted by Reuters, AbbVie’s action is the latest escalation in a long-running tug-of-war between manufacturers and providers over 340B. The lawsuit plants a North Chicago company, along with the hospitals that depend on 340B discounts, squarely in the middle of a policy fight that could reshape who can tap into some of the steepest drug discounts in the system. We will be watching for new filings and reactions from HRSA and hospital advocates as the case moves forward.
